Notice · For research and educational reference. Not medical advice. Intended for licensed professionals. Nothing on this site is offered for sale other than informational access.

All Info Peptides
All monographs

Healing & Tissue Repair

Pentadeca Arginate

Also known as · PDA · BPC-157 arginate salt · PDA-157

Sign in to follow PDF for subscribers

Overview

An arginate-salt form of the BPC-157 sequence, prepared for improved stability in solution. Increasingly used in place of the acetate salt in tissue-repair research.

Research profile · for clinicians

Based on research: the repair pharmacology is inherited from the BPC-157 literature; what differs is formulation chemistry. No head-to-head trial has compared arginate against acetate in humans.

Mechanism of action

Same pentadecapeptide sequence as BPC-157 — angiogenic VEGFR2 signalling, nitric-oxide modulation, and fibroblast outgrowth — with the arginate counter-ion intended to reduce degradation in solution.

Research record

  • [01]Rests on the ~25-year BPC-157 preclinical body of work.
  • [02]No published comparative pharmacokinetic study of the arginate versus acetate form.

Selected references

  • Stable gastric pentadecapeptide BPC 157 in clinical trials

    Curr. Pharm. Des., 2010

Research deep dive

Every cited study, explained

Plain-language walkthroughs of each reference, with direct PubMed links and dosing-literature context.